75 patents
Page 2 of 4
Utility
ANTI-SIGLEC-5 Antibodies and Methods of Use Thereof
6 Oct 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Kate MONROE, Helen LAM, Patricia CULP, Arnon ROSENTHAL
Filed: 9 May 22
Utility
Anti-SIRPa Antibodies and Methods of Use Thereof
15 Sep 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Andrew Pincetic, Wei-Hsien Ho, Patricia Culp, Arnon Rosenthal
Filed: 29 Mar 22
Utility
Anti-TMEM106B antibodies and methods of use thereof
13 Sep 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal antibodies, antibody fragments, etc., that specifically bind a TMEM106B polypeptide, e.g., a mammalian TMEM106B or human TMEM106B, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Arnon Rosenthal, Eric Brown, Tina Schwabe, Angie Yee, Herve Rhinn
Filed: 21 Dec 18
Utility
ANTI-CD33 Antibodies and Methods of Use Thereof
8 Sep 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Arnon ROSENTHAL, Kate MONROE, Francesca AVOGADRI-CONNORS
Filed: 24 May 22
Utility
ANTI-CD33 Antibodies and Methods of Use Thereof
11 Aug 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Kate MONROE, Helen LAM, Francesca AVOGADRI-CONNORS, Seung-Joo LEE, William MONTEITH, Herve RHINN, Arnon ROSENTHAL
Filed: 27 Aug 21
Utility
Methods of Use of Anti-sortilin Antibodies for Treating a Disease, Disorder, or Injury
11 Aug 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS, Robert PEJCHAL, Anthony B. COOPER
Filed: 14 Apr 22
Utility
Anti-Sortilin antibodies and methods of use thereof
26 Jul 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, affinity-matured, humanized antibodies, antibody fragments, etc., that specifically bind a Sortilin protein, e.g., human Sortilin or mammalian Sortilin, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Tina Schwabe, Michael Kurnellas, Arnon Rosenthal, Robert Pejchal, Anthony B. Cooper
Filed: 12 Jul 19
Utility
Anti-Siglec-7 antibodies and methods of use thereof
19 Jul 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-7 protein, e.g., human Siglec-7 or a mammalian Siglec-7, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Kate Monroe, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Francesca Avogadri-Connors, William Monteith
Filed: 14 Feb 20
Utility
Methods of Use of Anti-sortilin Antibodies for Treating a Disease, Disorder, or Injury
16 Jun 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS, Robert PEJCHAL, Anthony B. COOPER
Filed: 23 Nov 21
Utility
Methods of Increasing Progranulin Levels Using Anti-sortilin Antibodies
16 Jun 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
Arnon ROSENTHAL, Tina SCHWABE, Michael KURNELLAS, Robert PEJCHAL, Anthony B. COOPER
Filed: 23 Nov 21
Utility
Anti-siglec-5 antibodies and methods of use thereof
14 Jun 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Siglec-5 protein, e.g., human Siglec-5 or a mammalian Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Kate Monroe, Helen Lam, Patricia Culp, Arnon Rosenthal
Filed: 15 May 18
Utility
ANTI-CD33 Antibodies and Methods of Use Thereof
26 May 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Patricia CULP, Helen LAM, Arnon ROSENTHAL, Seung-Joo LEE, Nels P. NIELSON, Robert PEJCHAL
Filed: 21 Jan 22
Utility
Methods of use of anti-Sortilin antibodies for treating a disease, disorder, or injury
24 May 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
Arnon Rosenthal, Tina Schwabe, Michael Kurnellas, Robert Pejchal, Anthony B. Cooper
Filed: 8 Aug 18
Utility
Anti-SIRPA antibodies and methods of use thereof
3 May 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, antibodies, antibody fragments, etc., that specifically bind a SIRPA polypeptide, e.g., a mammalian SIRPA or human SIRPA, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Andrew Pincetic, Wei-Hsien Ho, Patricia Culp, Arnon Rosenthal
Filed: 24 May 19
Utility
Anti-CD33 antibodies and methods of use thereof
22 Feb 22
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind one or more epitopes within a CD33 protein, e.g., human CD33 or a mammalian CD33, and have improved and/or enhanced functional characteristics, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Patricia Culp, Helen Lam, Arnon Rosenthal, Seung-Joo Lee, Nels P. Nielson, Robert Pejchal
Filed: 7 May 20
Utility
Siglec Transgenic Mice and Methods of Use Thereof
6 Jan 22
Provided herein are transgenic non-human animals whose genomes comprise two or more human genes selected from CD33, Siglec-5, Siglec-7, Siglec-9, Siglec-11, Siglec-14, and Siglec-16, to methods of screening candidate agents that bind to and/or modulate the function and/or activity of at least one of the human genes in the transgenic non-human animals, and to methods of screening candidate agents to determine their effect on one or more activities and/or functions associated with expression of at least one of the human genes in the transgenic non-human animals.
Arnon ROSENTHAL, Seung-Joo LEE
Filed: 14 Sep 21
Utility
ANTI-APOE4 Antigen-binding Proteins and Methods of Use Thereof
30 Dec 21
The present disclosure generally relates to antigen-binding proteins (ABPs) that specifically bind to apolipoprotein E (ApoE), compositions comprising such ABPs, methods of using such ABPs, and methods of making such ABPs.
Arnon ROSENTHAL
Filed: 22 Jan 21
Utility
Methods of increasing progranulin levels using anti-Sortilin antibodies
28 Dec 21
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
Arnon Rosenthal, Tina Schwabe, Michael Kurnellas, Robert Pejchal, Anthony B. Cooper
Filed: 18 Sep 18
Utility
ANTI-SIGLEC-5 Antibodies and Methods of Use Thereof
23 Dec 21
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind a Siglec-5 protein, e.g., human Siglec-5, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Patricia CULP, Rashmi BANKOTI, Helen LAM, Arnon ROSENTHAL
Filed: 26 Jul 19
Utility
Isolated nucleic acids encoding anti-sortilin antibodies
30 Nov 21
The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
Arnon Rosenthal, Tina Schwabe, Michael Kurnellas, Robert Pejchal, Anthony B. Cooper
Filed: 13 Jan 20